文献速递炎症性肠病

难治性溃疡性直肠炎患者需要治疗升级:来自ENEIDA注册研究的PROCU研究结果

Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-28

基于ENEIDA前瞻性注册研究,共纳入34,716例溃疡性结肠炎患者,其中6,281例(18.1%)为溃疡性直肠炎。11%的患者需要免疫抑制治疗,4.2%需要至少一种生物制剂,多关节炎与需要免疫抑制剂相关(OR 3.56)。

要点

  • 溃疡性直肠炎占溃疡性结肠炎患者的18.1%。
  • 11%的难治性溃疡性直肠炎患者需要免疫抑制治疗。
  • 多关节炎患者需要免疫抑制剂的风险更高(OR 3.56)。

核心结论

  • 在难治性溃疡性直肠炎患者中,11%需要免疫抑制剂治疗,4.2%需要至少一种生物制剂。

研究设计与样本

  • 基于GETECCU赞助的ENEIDA前瞻性注册研究,识别溃疡性直肠炎患者,评估社会人口学数据及免疫抑制相关并发症。
  • 免疫抑制定义为使用免疫调节剂、生物制剂和/或小分子药物。
  • 采用逻辑回归分析识别与免疫抑制治疗相关的因素。

主要发现

  • 从34,716例溃疡性结肠炎患者中识别出6,281例(18.1%)溃疡性直肠炎患者,平均年龄53±15岁,平均病程12±9年。
  • 11%的患者接受了免疫抑制治疗,4.2%需要一种生物制剂,1%需要两种。
  • 2%的患者需要住院,0.5%接受了全直肠结肠切除术或次全结肠切除术。
  • 发现0.2%的结直肠肿瘤和5%的结肠外肿瘤。
  • 多关节炎患者需要免疫抑制剂(OR 3.56,95% CI 1.86-6.69;p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence, however, is scarce because these patients are excluded from randomised controlled clinical trials. Our aim was to describe the characteristics of patients with refractory UP and their disease-related complications, and to identify the need for immunosuppressive therapies. METHODS: We identified patients with UP from the prospective ENEIDA registry sponsored by the GETECCU. We evaluated socio-demographic data and complications associated with immunosuppression. We defined immunosuppression as the use of immunomodulators, biologics and/or small molecules. We used logistic regression to identify factors associated with immunosuppressive therapy. RESULTS: From a total of 34,716 patients with ulcerative colitis, we identified 6281 (18.1%) with UP; mean ± SD age 53 ± 15 years, average disease duration of 12 ± 9 years. Immunosuppression was prescribed in 11% of patients, 4.2% needed one biologic agent and 1% needed two; 2% of patients required hospitalisation, and 0.5% underwent panproctocolectomy or subtotal colectomy. We identified 0.2% colorectal tumours and 5% extracolonic tumours. Patients with polyarthritis (OR 3.56, 95% CI 1.86-6.69; p < 0.001) required immunosuppressants. CONCLUSIONS: Among patients with refractory UP, 11% required immunosuppressant therapy, and 4.2% required at least one biologic agent.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ferreiro-Iglesias R, Porto Silva S, Marín S, et al. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry. Aliment Pharmacol Ther. 2024. PMID: 38943230. doi:10.1111/apt.18133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。